[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2022, Vol. 44 ›› Issue (3): 198-207.doi: 10.16288/j.yczz.21-324

• Review • Previous Articles     Next Articles

Research progress of the correlation between genotype and phenotype in hypertrophic cardiomyopathy

Tian Shu1,2(), Haochang Hu1,2, Caijie Shen1, Shaoyi Lin1, Xiaomin Chen1,2()   

  1. 1. Ningbo Hospital of Zhejiang University, Ningbo 315000, China
    2. Zhejiang University School of Medicine, Hangzhou 310029, China
  • Received:2021-11-07 Revised:2021-12-27 Online:2022-03-20 Published:2022-01-10
  • Contact: Chen Xiaomin E-mail:shutian08@163.com;chxmin@hotmail.com

Abstract:

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic disease characterized by left ventricular hypertrophy with prevalence of 1/500-1/200. Up to now, 1500 mutations in more than 30 genes have been found to be related to the disease. Pathogenic gene mutations together with polymorphisms of modifying genes and environmental factors play various roles in the disease processes, resulting in phenotypic heterogeneity of the disease, ranging from no symptoms to sudden cardiac death. The pathological phenotypes of HCM mainly include cardiomyocyte hypertrophy, disordered array, fibrosis, myocardial ischemia, and others. In recent years, many research efforts have been devoted to exploring the influence of HCM genotype on phenotype, and development of treatment methods based on genetics. This article focuses on the correction between HCM genotype and phenotype and summarizes the research progresses on HCM in terms of pathogenic genes, pathogenesis, associated modification factors and treatment methods, thereby providing insights on the future research and development on the genetics of HCM.

Key words: hypertrophic cardiomyopathy, pathogenic genes, phenotype, treatment